Soligenix, Inc
Soligenix, Inc. is a U.S.-based late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases and other conditions with unmet medical need. Its pipeline is organized into two business segments: Specialized BioTherapeutics and Public Health Solutions, with programs spanning photodynamic therapy, inflammatory disease, and biodefense-related medical countermeasures.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage therapies for rare diseases and inflammatory conditions, including HyBryte™, SGX302, SGX942 and SGX945.
Programs and collaborations tied to public health, biodefense, and government-supported development work.
Customers
Soligenix does not sell to a broad commercial customer base in the way a mature pharmaceutical company does; its primary counterparties are clinical trial participants, research collaborators, government agencies, and potential future commercial partners. In the current stage of the business, value is created through development programs, grant-funded work, and eventual licensing or commercialization of approved therapies.
Patients with CTCL, psoriasis, oral mucositis, Behçet's disease, and related rare/inflammatory conditions enrolled in studies of the pipeline.
Public agencies and programs that support development work through grants, subawards, and research contracts.
Biopharma partners that may license, co-develop, or help commercialize product candidates after clinical success.
Future end users for approved therapies in dermatology, oncology, and inflammatory disease settings.
Strategy
The company’s strategy is to advance HyBryte™ through late-stage clinical development and seek regulatory approval for CTCL, while extending its synthetic hypericin platform into adjacent indications. It also pursues government support, partnerships, and other financing sources to fund development and preserve optionality across its pipeline.
Regulatory approval depends on successful confirmatory clinical data in CTCL.
Additional indications can increase the value of the core technology beyond CTCL.
Pipeline diversification reduces dependence on a single lead asset.
Development-stage biopharma programs require non-dilutive support and collaboration capital.
Geography
Soligenix is headquartered in the United States and conducts its development activities through a U.S.-based biopharmaceutical structure. Its programs are intended for worldwide regulatory pathways, including the U.S. FDA and the European Medicines Agency, so clinical and commercialization exposure is tied to both U.S. and international approval processes.
Risks
Soligenix faces the typical risks of a development-stage biopharmaceutical company: clinical trial failure, regulatory delay, manufacturing dependence, and competition from alternative therapies. Company-specific risks also include dilution from equity-linked securities and dependence on external financing to support ongoing development and operations.
- Clinical development failureImpact: CriticalLikelihood: Medium
Pipeline value depends on positive trial outcomes, especially for HyBryte™ and other candidates.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
Development spending exceeds current product revenue and the company relies on external capital sources.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
Products cannot be commercialized without FDA/EMA approval and the company has limited approval experience.
Exposure: U.S. and ex-U.S. commercialization
- Manufacturing and supply chain dependenceImpact: HighLikelihood: Medium
Clinical and commercial supply relies on third-party manufacturers meeting quality and timing requirements.
Exposure: Clinical trial supply and future commercial supply
- Competitive and technology riskImpact: Medium
Other companies may develop more effective or better-tolerated treatments for the same indications.
Exposure: Rare disease and inflammatory disease markets
Accounting
Judgemental itemsThe company recognized gains and later changed accounting treatment as debt terms were amended and repaid.
Impact: Can create non-cash volatility in other income and net loss
Revenue is tied to reimbursable research activity rather than product sales.
Impact: Creates low and uneven revenue tied to trial spending
Warrants, options, and at-the-market sales affect share count and capital structure.
Impact: Impacts EPS, dilution, and financing flexibility
The company states that future funding is needed to continue operations.
Impact: Important for assessing liquidity and financial statement assumptions
Similar listed companies
Publicly listed companies with a comparable business focus.
Soleno Therapeutics Inc
Pharmaceutical Preparations
SCYNEXIS, Inc
SCYX · Pharmaceutical Preparations
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Mosaic ImmunoEngineering Inc.
CPMV · Biological Products, (No Diagnostic Substances)
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Last updated: 24/09/2026